

Bio-Inspired Drug Delivery Systems: Lessons from Nature for Pharmaceutical Innovation

Jhanna¹, Aashish Kumar Netam², Ayushi Lingayya³, Ajita Khichariya³, Sandhya^{3*}

¹Chhatrapati Shivaji Institute of Pharmacy, Durg, Chhattisgarh, India. PIN-491001.

²Department of Zoology, Bhanupratap Deo Govt PG College, Kanker, Chhattisgarh, India.

³Kamla Institute of Pharmaceutical Sciences, Shri Shankaracharya Professional University, Junwani, Bhilai, Durg, Chhattisgarh, India. PIN-490020

*Corresponding Author E-mail: sandhyapharma17@gmail.com

Abstract:

Bio-inspired drug delivery systems are a relatively new area of development in the field of pharmaceutical science that applies the principles of nature to design a new system that will improve efficacy and safety in therapy. This is a review of recent developments in bio-inspired delivery platforms and, in particular, animal-based preclinical studies. Several biomimetic nanoparticles such as cell membrane-coated, exosome-mimetics, virus-inspired, and biomimetic polymers are critically analyzed. The areas of focus of this review include the methodology of fabrication, targeting mechanism, biodistribution studies and therapeutic studies in animal models. The major findings are that bio-inspired systems are much better in terms of drug stability, circulation time, and tissue specificity as compared to systemic toxicity reduction. Even though such results are promising, they are subject to such difficulties as scalability, reproducibility, and translational reliability. This review presents the contemporary developments, limitations, and future research directions to clinical translation.

Keywords: Bio-inspired drug delivery; Biomimetic nanocarriers; Targeted therapeutics; Nanomedicine; Biodistribution; Precision medicine.

Received: July 18, 2026

Revised: August 19, 2026

Accepted: September 15, 2026

Published: October 06, 2026

DOI: <https://doi.org/10.64063/3049-1681.vol3.issue10.000305>

This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY NC), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers. (<https://creativecommons.org/licenses/by-nc/4.0/>)

1. Introduction

Modern therapeutics is prone to poor bioavailability, nonspecific systemic clearance, dose-limiting toxicity, and difficulty in overcoming the challenges related to conventional drug delivery system that restrict the effectiveness of modern therapeutics. Such limitations are especially apparent when dealing with complex pathologies like cancer, neurological disorders, and chronic inflammatory conditions, where it is absolutely vital to precisely target and to regulate the shape of drug discharge to achieve therapeutic outcome. To address the challenges, bio-inspired drug delivery systems have become a promising family of sophisticated platforms

that imitate structural and functional characteristics of natural biological systems to increase pharmacological performance¹.

1.1. Background of the study

Traditional drug delivery vehicles are often crippled by serious drawbacks that comprise insolubility in aqueous solutions, brief systemic elimination, indiscriminate tissue partitioning, and dose restricting toxicity². These issues tend to cause diminished treatment efficacies and greater negative outcomes, especially in the treatment of complicated disorders like cancer, neurodegenerative disorders, inflammatory disorders, and metabolic disorders. Regardless of unremitting progress in the formulation of drugs, it is a significant challenge to the translational medicine field to attain accurate targeting and be able to control the release of drugs³.




Figure 1: Bio Bio-inspired drug delivery systems

In nature, there are very advanced and evolutionally efficient methods in molecular transport, cellular targeting, hostile environment protection and intercellular communication. Cells, viruses and extracellular vesicles are biological systems that are incredibly efficient in overcoming physiological barriers, identifying particular receptors, and transporting functional cargo to meet its targets⁴. Based on these naturally occurring systems, bio-inspired drug delivery platforms have become an attractive paradigm to counter the failure of the conventional therapeutics.

Recent advances in nanotechnology, materials science, and bioengineering have made it possible to fabricate delivery systems that mimic biological properties of membrane camouflage, ligandreceptor interactions, structural self-assembly, and adaptive responsiveness to microenvironmental stimuli. These are cell membrane-coated nanoparticles, exosome-mimetic vesicles, virus-inspired carriers, and biomimetic polymeric constructs⁵. These systems are aimed at optimizing the circulation time, avoiding immune detection, optimizing site-specific localization, and controlled release of the drug.

Preclinical animal models can be used to play a central role in determining the viability of such bio-inspired systems, before clinical translation⁶. The animal studies are important in the area of pharmacokinetics, biodistribution, immune compatibility, therapeutic effects, and safety. The

studies have been critical serving as the conduit between laboratory development and possible clinical application and so the researchers are able to assess biological interactions in complex living systems. Nonetheless, with promising results, scaling, reproducibility, chronic toxicity and translational predictability issues remain⁷.

1.2.Objectives of the Review

The primary objective of this review is to systematically analyse and synthesize findings from animal-based preclinical studies on bio-inspired drug delivery systems. Specifically, this review aims to:

- summarize major bio-inspired design strategies employed in pharmaceutical delivery;
- evaluate experimental methodologies and therapeutic outcomes reported in animal models;
- critically assess the strengths and limitations of current approaches; and
- identify key translational challenges and research gaps. By integrating evidence across diverse studies, this review seeks to provide a comprehensive understanding of the current landscape and developmental trajectory of bio-inspired delivery platforms.

1.3.Importance of the Topic

The growing chronic and complex disease burden in the world requires the development of sophisticated treatment approaches that can be used to target specific disease parts with minimal systemic toxicity occurrence. Bio-inspired drug delivery systems have a potential to revolutionize the field of medicine because they can use natural biological concepts to improve the exactness and efficacy of treatment⁸. They prove to be next-generation solutions in the field of pharmaceutical innovation, as they demonstrate the ability to enhance the stability of drugs, extend their circulation, and target accumulation.

Moreover, the emphasis on the animal-based preclinical evidence is a viable assessment of biological performance and translational viability. The integrated knowledge of these studies is imperative in the direction of future research, the best design of the system, and the speed at which this may advance to clinical implementation. Therefore, the review is part of the developing literature that would bring gaps between biomimetic engineering and real-life therapeutic implementation, which would facilitate safer and more efficient drug delivery technologies⁹.

2. Concept of Bio-Inspired Drug Delivery

Bio-inspired drug delivery systems are designed platforms which mimic structural, chemical or functional characteristics of natural biological objects to enhance therapeutic effect. The bio-inspired systems are especially beneficial in contrast to the conventional carriers that frequently experience rapid clearance, lack specific targeting, and are unable to respond to physiological conditions with adaptive response.

The main purposes of these systems are to increase the circulation lifetime, decrease opsonization, allow site-specific deposition, and regulate the liberation of drugs. Typically used

inspirations are cell membranes, extracellular vesicles, viral structures and naturally occurring polymers¹⁰. By incorporating these biological features into the synthetic constructs, scientists are aiming to recreate the effectiveness of the natural transport systems whilst preserving the engineering control of the size, composition and cargo.

In preclinical animal models, it has been shown that such biomimetic methods can be used to substantially better the pharmacokinetic profiles and therapeutic indices of pharmaceutical formulations, when compared to conventional formulations. Notably, these platforms can be further used to enable modular design and add targeting ligands, imaging agents, and stimuli-responsive elements¹¹. Consequently, bio-inspired delivery systems have become a convergence of nanotechnology, biomaterials science, and pharmacology and represent flexible methods of treating complicated diseases.

Table 1: Classification of Bio-Inspired Drug Delivery Systems

Bio-inspired Strategy	Natural Inspiration	Key Features	Typical Applications
Cell membrane-coated nanoparticles	RBCs, platelets, cancer cells	Immune evasion, homotypic targeting	Cancer therapy, inflammation
Exosome-mimetic systems	Extracellular vesicles	High biocompatibility, BBB penetration	Neurological disorders, tumors
Virus-inspired carriers	Viral capsids	Efficient cellular entry	Gene therapy, intracellular delivery
Biomimetic polymers/peptides	Mussel proteins, bacterial surfaces	Mucoadhesion, controlled release	Oral, transdermal, tumor targeting

2.1. Major Bio-Inspired Strategies Evaluated in Animal Models

Various prevailing bio-inspired paradigms have been investigated using animal subjects and all use different biological principles. The following are the themes of these approaches.

2.1.1. Cell Membrane-Coated Nanocarriers

One of the best-investigated bio-inspired delivery platforms is cell membrane coated nanoparticles. Under this mechanism, red blood cell, platelet, leukocyte or cancer cell membranes are used to cover synthetic nanoparticle cores. This membrane camouflage retains endogenous surface proteins, which permit immune-evasion and biological-recognition.

Murine tumor model Preclinical experiments with red blood cell membrane-coated nanoparticles have found that these particles have an extended systemic circulation, and are actively taken up

less by macrophages. The membrane coatings on the platelets improve the adhesion to the damaged vasculature and inflamed tissues, which localises when needed, such as at the site of disease¹². The homotypic targeting is made possible by cancer cell membrane coatings whereby nanoparticles accumulate preferentially in tumors of the same cell type.

Animal studies always claim superior accumulation of tumor, better therapeutic performance, and less off-target toxicity than uncoated nanoparticles. Nevertheless, there are still issues in terms of variability of membrane sources, batch-to-batch reproducibility, and large scale manufacturing. Besides, the long-term immunological effects of repeated administration are not clearly known¹³.

2.1.2. Exosome-Mimetic Delivery Systems

Exosome-based systems seek to mimic the cellular functionality of extracellular vesicles as an intercellular communicant. These vesicles inherently have biocompatibility, low immunogenicity and inherent targeting properties and so, they are of interest in drug delivery.

Exosome-mimetic carriers have been shown to be efficiently penetrated into the tissues and have the capacity to penetrate biological barriers such as blood-brain barrier in animal models. Preclinical studies have been conducted using such properties in neurological disorders and in metastatic cancers¹⁴. What is even more important is that therapeutic payloads that are delivered through these systems have better cellular uptake and better functional outcomes than traditional nanocarriers.

Although these have the stated benefits, they have drawbacks such as low natural source yield, vesicle heterogeneity, and characterization difficulties. Mimetic exosome systems based on synthetic exosomes partially overcome the scalability, but at the cost of biological fidelity.

2.1.3. Virus-Inspired Nanoparticles

The highly organized structures and effective cellular entry mechanisms of viral particles are used in the production of virus-inspired nanoparticles. The engineered systems resemble the size and structure of viruses and surface functionality without the pathogenic genes contained therein¹⁵.

Animal experiments have shown that virus-mimicking carriers are better than others at intracellular delivery of genes and small-molecule drugs because of maximized endocytosis and endosomal escape. These are of special importance to gene therapy and intracellular drug targeting.




Figure 2: Virus-inspired nano particles

Nevertheless, there is a serious issue of immunogenicity. Viral mimics do not always need to be infectious to induce an immune response, which may restrict chronic administration. Also, their translational potential is complicated by the complex fabrication processes and regulatory issues.

2.1.4. Biomimetic Polymers and Peptide-Based Systems

Biomimetic polymers and biomimetic carriers based on peptide are inspired by the naturally occurring materials like mussel adhesive proteins, bacterial surfaces, and self-assembling peptides¹⁶. The aim of these systems is to have an improved mucoadhesion, environmental responsiveness, and controlled release.

Experiments in animals demonstrate that these platforms enhance retention at mucosal surfaces, allow prolonged release of drugs and site-specific accumulation in inflamed or cancerous tissues. Particularly, peptide systems have high accuracy in molecular programmability and biodegradability.

However, the kinetics of polymer degradation, mechanical stability, and the toxicity of the possible metabolites need to be investigated¹⁷. Also, there is still a challenge in translating the laboratory scale synthesis to the industrial manufacturing process.

3. METHODOLOGIES USED

The majority of preclinical studies are based on murine or rat models to test the biological performance and therapeutic effects. Typical experimental outcomes are:

- Pharmacokinetics and biodistribution measured by fluorescence imaging, radiolabeling, or mass spectrometry.
- Targeting efficiency determined by tissue accumulation and cellular uptake experiments.

- The therapeutic effect assessed by disease-specific parameters like shrinking of the tumor, behavioral change, or inflammatory response.
- Safety profiles identified based on hematological analysis, histopathology, and acute toxicity studies or chronic toxicity studies.

These techniques are informative about the behavior in vivo, although there is a considerable variance in studies of species of animals, dosing schedules, imaging, and timelines of evaluation¹⁸. This heterogeneity makes it difficult to compare and conduct meta-analysis. Additionally, small animal models, used as an alternative, might not be able to effectively predict the pharmacological action of large organisms, and this point sets precedence to the standardization of procedures and multi-species testing.

3.1. Critical Evaluation

The bio-inspired drug delivery system has become an emerging promising therapy paradigm with significant control advantages, including precision of targeting, safety, and versatile structure. Using natural biological pathways, these platforms have shown an improved disease-site accumulation and superior therapeutic effect in preclinical models, and allow the therapeutic capabilities to be incorporated and diagnostic capabilities to be incorporated on a modular basis¹⁹. Nevertheless, even with these strengths, there are significant weaknesses, such as a lack of long-term safety data, variability during manufacturing, and scaling limitations, and uncertainty about clinical translation. The subsequent paragraphs have highlighted the main strengths and weaknesses that characterize presently the developmental scenario of bio-inspired drug delivery technologies.

- **Strengths**

The bio-inspired drug delivery systems continually show an improvement in targeting, reduced systemic toxicity and therapies indexes in the animal models. They can be used to accumulate in disease sites and reduce off-target exposure due to their capability to use biological recognition pathways. Also, theranostic applications can be integrated with diagnostic and therapeutic functions by means of modular design strategies.

- **Weaknesses**

Although the results are promising, a number of shortcomings are still present. There is limited data on long term safety especially of immune memory and chronic exposure. The standards of manufacturing are not standardized, and there is a problem of reproducibility. Massive production is technically challenging particularly to membrane-based systems and vesicle-derived systems.

Table 2 provides a narrow scope perspective of the most important literature on bio-inspired drug delivery systems, describing the shift in biomimetic approaches in the system design and use of biomimetic strategies in the translational context. The studies, as a whole, highlight membrane-coated nanoparticles, biomimetic carriers, biomaterials based on natural polymers, and systems driven by biomolecules as the focal points towards enhancing the efficiency of targeting and the therapeutic capabilities. The reviewed articles cover the basic principles of design, fabrication methods, as well as biomedical applications in real life, and also discuss such

new challenges as scalability and clinical translation. Comprehensively, the table shows a gradual transition to the incorporation of biology and materials science to create intelligent and adaptive drug delivery platforms, which highlights the maturity and interdisciplinarity of the given field of research.

Table 2. Review of Literature on Bio-Inspired Drug Delivery Systems

Author Name	Topic Covered	Research Study Title
Neubi et al. (2018) ²⁰	Bio-inspired drug delivery strategies for targeted cancer therapy, including membrane-coated nanoparticles and biomimetic carriers	Bio-inspired drug delivery systems: an emerging platform for targeted cancer therapy
Tong et al. (2020) ²¹	Progress and recent advances in bioinspired drug delivery systems, focusing on design principles and translational challenges	Research progress in bioinspired drug delivery systems
Villalba-Rodriguez et al. (2017) ²²	Bio-inspired biomaterials and their applications in drug delivery, highlighting natural polymers and biomimetic platforms	Bio-inspired biomaterials and their drug delivery perspectives – A review
Tomić (2023) ²³	Comprehensive overview of bio-inspired drug delivery approaches, including fabrication methods and therapeutic applications	Bio-inspired drug delivery systems
Barman & Das (2024) ²⁴	Bio-inspired product development and technological innovation with relevance to pharmaceutical and biomedical applications	Bio-Inspired Products and Technology Innovation – The Present and Future
Hou & Yu (2025) ²⁵	Biomolecule-driven smart drug delivery systems integrating biology and materials science for advanced therapeutic delivery	The convergence of biology and material science: Biomolecule-driven smart drug delivery systems

4. DISCUSSION

The Discussion section summarizes important findings of animal-based preclinical tests in an attempt to critically analyze the performance, translationality, and future research of bio-inspired drug delivery systems²⁶. Using evidence-based approaches through a multiplicity of biomimetic platforms containing cell membrane-coated nanoparticles, exosome-inspired carriers, virus-inspired systems, and biomimetic polymers, this section decodes therapeutic result(s) by comparing them to design principles and experimental approaches²⁷. It focuses on the importance of understanding how biological inspiration can improve targeting efficiency, biodistribution or safety profiles and overcome shortcomings originating in model variability, manufacturing complexity, and evaluations not yet finished²⁸. Moreover, this part discusses the general implications of these findings on the pharmaceutical innovation dimension and critical research gaps that need to be filled to enable clinical translation²⁹.

4.1. Interpret and analyse the findings.

The cumulative data obtained with the preclinical experiments of the animals prove that bio-inspired drug delivery system is absolutely superior to the traditional formulations in the aspect of targeting, the duration of circulation and the therapeutic efficacy³⁰. After imitating the natural biological processes of membrane camouflage, receptor-mediated recognition, and vesicular transport, these platforms demonstrate improved biodistribution profile and lower off-target accumulation. In various types of disease models such as cancer, neurological, and inflammatory diseases, bio-inspired carriers have been shown to deliver a better payload and show better therapeutic activity³¹.

Nanoparticles coated with cell membrane have a long systemic circulation and immune escape, making it an effective targeting of the pathological site³². Exosome-mimetic systems offer inherent biocompatibility and efficient penetration through the biological barriers especially the bloodbrain barrier. Nanoparticles based on viruses have been designed to have optimized cellular uptake facilitating effective intracellular drug and gene transfer³³. The biomimetic polymers and peptide based systems exhibit regulated release characteristics and localised retention. Taken together, the results point to the versatility and flexibility of bio-inspired strategies to various therapeutic scenarios³⁴.

Nonetheless, although these positive preclinical findings have been achieved, the variability in the way studies were conducted prevents the direct comparison between studies³⁵. The variation in animal species, model diseases, dosing and the use of imaging techniques adds heterogeneity which makes it difficult to come up with standard benchmarks³⁶. Furthermore, most studies focus on the short-term effectiveness but gives minimal coverage to long-term safety and immunological effects. Consequently, despite the evident benefits of bio-inspired systems at the preclinical stage, it is not yet clear whether they are reliable at the translational level³⁷.

4.2. Implications and Significance

The proved effectiveness of bio-based drug delivery systems in animal models has an enormous potential impact on the innovation of pharmaceuticals³⁸. These systems target the age-old problems in drug delivery such as rapid clearance, nonspecific distribution and dose limiting toxicity³⁹. They can utilize the natural recognition pathways that they can targeted with high precision and with minimal systemic exposure, thereby enhancing therapeutic indices⁴⁰.

Clinically, these developments would change the paradigm of treatment of complicated diseases requiring local or intracellular drug activity⁴¹. Moreover, bio-inspired platforms are modular, which enables the incorporation of diagnostic agents, which opens up the possibilities of theragnostic applications⁴². These systems marked a move away towards biologically intelligent therapeutics, as the convergence of nanotechnology, biomaterials engineering, and pharmacology is also expressed in nanotechnology⁴³.

On a larger scale, animal testing of these platforms enhances the trust in the ideas of biomimetic design and promotes their further evolution⁴⁴. These results highlight the significance of preclinical modelling to optimize the formulation parameters and to determine the biological interactions before clinical translation. Bio-inspired drug delivery systems are therefore an excellent alternative to the development of the future generation of pharmaceuticals^{45,46}.

4.3. Research Gaps and Future Directions

- Absence of standardized assessment systems is still a significant challenge because the variation in animal models, outcomes, and trial designs restrict cross-study comparability and systematic performance evaluation.
- This is due to inadequate research on long-term toxicity and immunogenicity, most of the studies focus on the acute effects but not chronic effects of exposure.
- Lack of methods of fabrication that can be duplicated especially in membrane-derived and vesicle-based systems is a cause of concern as to whether there is quality control and consistency of batches.
- Scalability has remained a problem, as most bio-inspired platforms rely on the multistage process, which is hard to scale to industrial manufacturing.
- The future research needs to focus on comparative studies in more than one animal model (including large animals) to enhance the predictability in translation.
- Real-time biodistribution, clearance and therapeutic response require integration of superior imaging and tracking technologies.

5. CONCLUSION

The bio-inspired drug delivery systems have become a potent paradigm in the contemporary therapeutics as they provide novel approaches to the problems of drug stability, specificity in targeting, and systemic safety. Based on the biological processes occurring in nature, these next-generation platforms combine biomaterials science, nanotechnology and pharmacology to improve in vivo performance and therapeutic targeting. In this regard, the current review summarizes recent animal-based preclinical studies to critically analyse the design considerations, functionality merits and translational capability of the biomimetic delivery systems. This conclusion recaps the main key insights obtained during the synthesis of the

experimental results of various platforms and disease models, highlights the overall importance of such technologies, and provides research and clinical development strategies in the future.

5.1. Summary of Main Insights and Conclusions

This review has broadly explored animal-based preclinical research on bio-inspired drug delivery systems, and it has brought out its ability to address major drawbacks of traditional pharmaceutical formulations. Through biomimetic self-assembly, receptor-mediated targeting, vesicular transport, and membrane camouflage, these platforms are shown to exhibit greater drug stability, longer circulation, increased and more precise targeting, and better therapeutic efficacy in a variety of disease models. Exosome-mimetic carriers such as cell membrane-coated nanoparticles, virus-inspired systems and biomimetic polymers are all examples of how bio-inspired approaches can enhance drug performance in vivo.

5.2.Importance of the Review

- Discusses the growing significance of bio-inspired delivery systems as breakthroughs in pharmaceuticals.
- To support their future in next generation precision medicine, they provide proof, through animal studies, of their ability to decrease systemic toxicity and improve therapeutic efficacy.
- Asserts the importance of preclinical modeling in bio mimetic approaches to drug validation and rational design, prior to clinical translation.
- Sums up the varying experimental results to describe a systematic review of existing developments, constraints, and limitations of future research in this fast-changing field.

5.3.Recommendations and Future Perspectives

- Institute standardized preclinical assessment models that will enhance consistency, reproducibility, and cross-study differences.
- Do extensive long-term toxicity and immunogenicity testing to determine long term safety and biological compatibility.
- Establish repeatable and scalable fabrication approaches to facilitate bio-inspired delivery platform industrial translation.
- Conduct comparative research on various animal models, such as large animals, in order to improve translational precision.
- Introduce real-time evaluation of biodistribution and therapeutic effect based on the advanced imaging and tracking.
- Encourage early regulatory consistency and interdisciplinary cooperation among biomaterials scientists, pharmacologists, engineers and clinicians to hasten clinical execution.

References

1. Harun-Ur-Rashid, M., Jahan, I., Foyez, T., & Imran, A. B. (2023). Bio-inspired nanomaterials for micro/nanodevices: a new era in biomedical applications. *Micromachines*, 14(9), 1786.

2. Liu, X., Fei, Y., Cui, B., Chen, X., Zhang, J., Yue, O., ... & Jiang, H. (2025). Bio-inspired natural fibers-derived e-skin equipped with intelligent drug-release system for advanced robustly-integrated melanoma therapy. *Collagen and Leather*, 7(1), 28.
3. Zhang, M., Zang, X., Wang, M., Li, Z., Qiao, M., Hu, H., & Chen, D. (2019). Exosome-based nanocarriers as bio-inspired and versatile vehicles for drug delivery: recent advances and challenges. *Journal of Materials Chemistry B*, 7(15), 2421-2433.
4. Kim, M. W., Kwon, S. H., Choi, J. H., & Lee, A. (2018). A promising biocompatible platform: Lipid-based and bio-inspired smart drug delivery systems for cancer therapy. *International journal of molecular sciences*, 19(12), 3859.
5. Jawadi, Z., Yang, C., Haidar, Z. S., Santa Maria, P. L., & Massa, S. (2022). Bio-inspired muco-adhesive polymers for drug delivery applications. *Polymers*, 14(24), 5459.
6. Briolay, T., Petithomme, T., Fouet, M., Nguyen-Pham, N., Blanquart, C., & Boisgerault, N. (2021). Delivery of cancer therapies by synthetic and bio-inspired nanovectors. *Molecular Cancer*, 20(1), 55.
7. Abudurexiti, M., Zhao, Y., Wang, X., Han, L., Liu, T., Wang, C., & Yuan, Z. (2023). Bio-inspired nanocarriers derived from stem cells and their extracellular vesicles for targeted drug delivery. *Pharmaceutics*, 15(7), 2011.
8. Tiwari N, Sahu MK, Kashyap G, Pandey AP, Verma VS. Systematic review of smart nanoplatfroms in liver, breast, kidney, and brain cancers: Targeted delivery, omics, and therapy response. *Journal of Pharmaceutical Research and Integrated Medical Sciences*. 2026;3(2).
9. Bojarska, J., & Wolf, W. M. (2020, December). Ultra-short cyclo-peptides as bio-inspired therapeutics: Proline-based 2, 5-diketopiperazines (DKP). In *Proceedings* (Vol. 79, No. 1, p. 10). MDPI.
10. Kim, Y. S., & Shin, Y. S. (2024). Surface Functionalization of 3D-Printed Bio-Inspired Scaffolds for Biomedical Applications: A Review. *Biomimetics*, 9(11), 703.
11. Nawaz, T., Gu, L., Gibbons, J., Hu, Z., & Zhou, R. (2024). Bridging nature and engineering: Protein-derived materials for bio-inspired applications. *Biomimetics*, 9(6), 373.
12. Bhattacharya, T., Rather, G., Akter, R., Kabir, M. T., Rauf, A., & Rahman, M. (2021). Nutraceuticals and bio-inspired materials from microalgae and their future perspectives. *Current Topics in Medicinal Chemistry*, 21(12), 1037-1051.
13. Masouleh, M. M. (2024). Numerical and experimental investigation of enhancing transdermal model drug delivery: a study on bio-inspired microneedles and iontophoresis integration (Doctoral dissertation, University of Victoria).
14. Ezike, T. C., Okpala, U. S., Onoja, U. L., Nwike, C. P., Ezeako, E. C., Okpara, O. J., ... & Nwanguma, B. C. (2023). Advances in drug delivery systems, challenges and future directions. *Heliyon*, 9(6).
15. Adepu, S., & Ramakrishna, S. (2021). Controlled drug delivery systems: current status and future directions. *Molecules*, 26(19), 5905.
16. Sung, Y. K., & Kim, S. W. (2020). Recent advances in polymeric drug delivery systems. *Biomaterials Research*, 24(1), 12.

17. Park, H., Otte, A., & Park, K. (2022). Evolution of drug delivery systems: From 1950 to 2020 and beyond. *Journal of Controlled Release*, 342, 53-65.
18. Liu, D., Yang, F., Xiong, F., & Gu, N. (2016). The smart drug delivery system and its clinical potential. *Theranostics*, 6(9), 1306.
19. Jain, K. K. (2019). An overview of drug delivery systems. *Drug delivery systems*, 1-54.
20. Neubi, G. M. N., Opoku-Damoah, Y., Gu, X., Han, Y., Zhou, J., & Ding, Y. (2018). Bio-inspired drug delivery systems: an emerging platform for targeted cancer therapy. *Biomaterials science*, 6(5), 958-973.
21. Tong, Q., Qiu, N., Ji, J., Ye, L., & Zhai, G. (2020). Research progress in bioinspired drug delivery systems. *Expert Opinion on Drug Delivery*, 17(9), 1269-1288.
22. Villalba-Rodriguez, A. M., Parra-Saldivar, R., Ahmed, I., Karthik, K., Malik, Y. S., Dhama, K., & Iqbal, H. (2017). Bio-inspired biomaterials and their drug delivery perspectives-A review. *Current drug metabolism*, 18(10), 893-904.
23. Tomić, S. L. (2023). Bio-inspired drug delivery systems. In *Advanced and Modern Approaches for Drug Delivery* (pp. 683-702). Academic Press.
24. Barman, A., & Das, K. (2024). Bio-Inspired Products and Technology Innovation-The Present and Future. *International Journal of Innovative Research in Engineering and Management*, 11(3), 25-33.
25. Hou, Y., & Yu, X. (2025). The convergence of biology and material science: Biomolecule-driven smart drug delivery systems. *Biomolecules*, 15(10), 1383.
26. Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Rodriguez-Torres, M. D. P., Acosta-Torres, L. S., ... & Shin, H. S. (2018). Nano based drug delivery systems: recent developments and future prospects. *Journal of nanobiotechnology*, 16(1), 71.
27. Bhatia, S. (2016). *Natural polymer drug delivery systems* (pp. 33-93). Basel, Switzerland: Springer international publishing.
28. Homayun, B., Lin, X., & Choi, H. J. (2019). Challenges and recent progress in oral drug delivery systems for biopharmaceuticals. *Pharmaceutics*, 11(3), 129.
29. Din, F. U., Aman, W., Ullah, I., Qureshi, O. S., Mustapha, O., Shafique, S., & Zeb, A. (2017). Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. *International journal of nanomedicine*, 7291-7309.
30. Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022). Drug delivery systems for RNA therapeutics. *Nature Reviews Genetics*, 23(5), 265-280.
31. Badwaik HR, Kumari L, Nakhate K, Verma VS, Sakure K. Phytoconstituent plumbagin: Chemical, biotechnological and pharmaceutical aspects. *Studies in Natural Products Chemistry*. 2019;63:415-460. doi:10.1016/B978-0-12-817901-7.00013-7
32. Saghazadeh, S., Rinoldi, C., Schot, M., Kashaf, S. S., Sharifi, F., Jalilian, E., ... & Khademhosseini, A. (2018). Drug delivery systems and materials for wound healing applications. *Advanced drug delivery reviews*, 127, 138-166.
33. Tanwar DS, Kashyap G, Pandey A, Mahant H, Verma VS. Structure-Based Drug Design of Kinase Inhibitors for Targeted Cancer Therapy. *Indian Journal of Pharmaceutical Chemistry and Analytical Techniques*. Published online 2025:136-148. doi:10.64062/IJPCAT.VOL1.ISSUE4.11

34. Chandrakala, V., Aruna, V., & Angajala, G. (2022). Review on metal nanoparticles as nanocarriers: Current challenges and perspectives in drug delivery systems. *Emergent Materials*, 5(6), 1593-1615.
35. Kashyap G, Pandey AP, Tiwari NT, Sahu MK, Verma VS. Meta-Analysis of Multi-Omics and Nanoparticle-Enhanced Therapeutics in Solid Tumors: Advancing Precision Oncology. *Journal of Pharmaceutical Research and Integrated Medical Sciences*. Published online February 18, 2026:63-76. doi:10.64063/3049-1681.VOL.3.ISSUE2.5
36. Dou, Y., Li, C., Li, L., Guo, J., & Zhang, J. (2020). Bioresponsive drug delivery systems for the treatment of inflammatory diseases. *Journal of Controlled Release*, 327, 641-666.
37. Dohre PD, Verma VSV, Singh NS, Singh NS, Kumar DK. Phytopharmacology in the Nanotech Era: Bridging Natural Compounds with Pharmaceutical Nanocarriers. *Journal of Pharmacology, Genetics and Molecular Biology*. Published online February 12, 2026:45-67. doi:10.64062/JPGMB.VOL2.ISSUE1.4
38. Ramadan, D., McCrudden, M. T., Courtenay, A. J., & Donnelly, R. F. (2022). Enhancement strategies for transdermal drug delivery systems: Current trends and applications. *Drug delivery and translational research*, 12(4), 758-791.
39. Yoo, J. W., Irvine, D. J., Discher, D. E., & Mitragotri, S. (2011). Bio-inspired, bioengineered and biomimetic drug delivery carriers. *Nature reviews Drug discovery*, 10(7), 521-535.
40. Jahanban-Esfahlan, R., Derakhshankhah, H., Haghshenas, B., Massoumi, B., Abbasian, M., & Jaymand, M. (2020). A bio-inspired magnetic natural hydrogel containing gelatin and alginate as a drug delivery system for cancer chemotherapy. *International journal of biological macromolecules*, 156, 438-445.
41. Verma VS, Sharma G. Determining Extractable Phthalates in Pharmaceutical Products Using Lcms/Ms. *Indian Journal of Pharmaceutical Chemistry and Analytical Techniques*. Published online June 2, 2025:38-50. Accessed January 9, 2026.
42. Parodi, A., Molinaro, R., Sushnitha, M., Evangelopoulos, M., Martinez, J. O., Arrighetti, N., ... & Tasciotti, E. (2017). Bio-inspired engineering of cell-and virus-like nanoparticles for drug delivery. *Biomaterials*, 147, 155-168.
43. Alvarez-Lorenzo, C., & Concheiro, A. (2013). Bioinspired drug delivery systems. *Current opinion in biotechnology*, 24(6), 1167-1173.
44. Ming, L., Wu, H., Fan, Q., Dong, Z., Huang, J., Xiao, Z., ... & Li, Z. (2024). Bio-inspired drug delivery systems: A new attempt from bioinspiration to biomedical applications. *International Journal of Pharmaceutics*, 658, 124221.
45. Lo, C., Bhardwaj, K., & Marculescu, R. (2017). Towards cell-based therapeutics: A bio-inspired autonomous drug delivery system. *Nano communication networks*, 12, 25-33.
46. Dharne CS, et al. Theranostic liposomes: Dual-function nanocarriers for drug delivery and disease monitoring. 2026.